Arrowhead Pharmaceuticals Inc (ARWR)
24.02
-0.68
(-2.75%)
USD |
NASDAQ |
Apr 15, 16:00
24.01
-0.01
(-0.04%)
After-Hours: 20:00
Arrowhead Pharmaceuticals Cash from Financing (TTM): 2.744M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 2.744M |
| September 30, 2023 | 253.05M |
| June 30, 2023 | 253.76M |
| March 31, 2023 | 312.55M |
| December 31, 2022 | 313.88M |
| September 30, 2022 | 65.19M |
| June 30, 2022 | 65.15M |
| March 31, 2022 | 7.301M |
| December 31, 2021 | 8.088M |
| September 30, 2021 | 11.30M |
| June 30, 2021 | 11.50M |
| March 31, 2021 | 10.87M |
| December 31, 2020 | 9.572M |
| September 30, 2020 | 257.95M |
| June 30, 2020 | 258.78M |
| March 31, 2020 | 259.41M |
| December 31, 2019 | 260.75M |
| September 30, 2019 | 66.38M |
| June 30, 2019 | 66.12M |
| March 31, 2019 | 64.81M |
| December 31, 2018 | 119.04M |
| September 30, 2018 | 59.95M |
| June 30, 2018 | 58.26M |
| March 31, 2018 | 56.81M |
| December 31, 2017 | 0.046M |
| Date | Value |
|---|---|
| September 30, 2017 | 12.06M |
| June 30, 2017 | 65.82M |
| March 31, 2017 | 68.03M |
| December 31, 2016 | 67.66M |
| September 30, 2016 | 55.13M |
| June 30, 2016 | 1.625M |
| March 31, 2016 | -0.6335M |
| December 31, 2015 | -0.3844M |
| September 30, 2015 | 0.2905M |
| June 30, 2015 | 0.6894M |
| March 31, 2015 | 5.085M |
| December 31, 2014 | 122.71M |
| September 30, 2014 | 185.29M |
| June 30, 2014 | 186.76M |
| March 31, 2014 | 217.72M |
| December 31, 2013 | 103.78M |
| September 30, 2013 | 44.29M |
| June 30, 2013 | 47.79M |
| March 31, 2013 | 15.14M |
| December 31, 2012 | 12.62M |
| September 30, 2012 | 10.77M |
| June 30, 2012 | 9.716M |
| March 31, 2012 | 7.077M |
| December 31, 2011 | 7.615M |
| September 30, 2011 | 6.226M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
2.744M
Minimum
Dec 2023
313.88M
Maximum
Dec 2022
131.28M
Average
66.12M
Median
Jun 2019
Cash from Financing (TTM) Benchmarks
| Madrigal Pharmaceuticals Inc | 595.12M |
| Viking Therapeutics Inc | 271.38M |
| Akero Therapeutics Inc | 353.32M |
| 89bio Inc | 513.11M |
| Sagimet Biosciences Inc | 86.17M |